Michael Zezas: U.S./China Trade - No Quick Path to Lower Barriers
Most Trump era barriers remain in place and new ones may even be implemented by the current administration. Markets should pay attention.
24 Maalis 20212min
Brian Nowak: New Online Habits vs. A Return to ‘Normal’
The Internet sector is more essential than ever. Our analyst looks at where pandemic habits will be stickiest and where the return to ‘normal’ may limit it.
23 Maalis 20214min
Mike Wilson: Outside the Consensus
We forecast a shorter and hotter business cycle than the consensus estimates, suggesting a move to mid-cycle portfolio positions earlier than expected.
22 Maalis 20213min
Special Episode: The Winding Road to Herd Immunity, Pt. 2
Chief Cross-Asset Strategist Andrew Sheets and Biotech equity analyst Matthew Harrison continue their conversation, with a focus on international progress for COVID-19 vaccinations.
19 Maalis 20218min
Special Episode: The Winding Road to Herd Immunity
Chief Cross-Asset Strategist Andrew Sheets talks with Biotech equity analyst Matthew Harrison on dose availability, vaccine hesitancy and the timeline for herd immunity.
18 Maalis 20219min
Michael Zezas: Three Revealing Numbers from the Stimulus Package
It may be hard for investors to conceptualize how substantial the impact of the American Rescue Plan Act may be, but three numbers provide perspective.
17 Maalis 20212min
Chetan Ahya: Fed Tightening Could Come Sooner than Expected
With the rapid recovery of the U.S. economy, it is possible that inflation will overshoot the Fed’s tolerances by as early as mid-2022.
16 Maalis 20214min
Mike Wilson: A Tougher Road Ahead for Small Caps?
After almost a year of extraordinary outperformance, could small caps could see more difficulties ahead as re-opening dynamics up the risk of cost pressures?
15 Maalis 20213min
